Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for resisting liver cancer by inhibiting carnitine palmityl transferase 1B (CPT1B)

A technology for inhibiting liver cancer and transferase, applied in the field of medicine, can solve the problems of poor prognosis, less than 20% survival rate of patients, and difficult treatment, and achieve the effect of clear curative effect, good clinical application prospect and clear mechanism.

Pending Publication Date: 2020-07-14
ZUNYI MEDICAL UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hepatocellular carcinoma is not easy to detect in the early stage, and it often develops to the middle and late stage when it is clinically diagnosed. It is difficult to treat and the prognosis is poor. The 5-year survival rate of patients is less than 20%.
[0007] At present, the Argentinogenin mentioned in the present invention inhibits carnitine acyltransferase 1B (CPT1B) through the JAK / STAT3 signaling pathway, reduces the β-oxidation of fatty acid in liver cancer cells, and inhibits the growth, invasion and metastasis of liver cancer cells. There is no research at home and abroad any reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for resisting liver cancer by inhibiting carnitine palmityl transferase 1B (CPT1B)
  • Drug for resisting liver cancer by inhibiting carnitine palmityl transferase 1B (CPT1B)
  • Drug for resisting liver cancer by inhibiting carnitine palmityl transferase 1B (CPT1B)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1A

[0039] Embodiment 1Argentinogenin inhibits the expression of carnitine acyltransferase 1B (CPT1B) by down-regulating JAK / STAT3, and then inhibits the invasion and metastasis of liver cancer SMMC-7721 cells

[0040]Cell proliferation was detected by SRB method. Argentinogenin was diluted to the following concentrations: 3.125, 6.25, 12.5, 25, 50 and 100 nM. SMMC-7721 cells in the logarithmic growth phase were seeded in 96-well plates at a seeding density of 8×10 3 Each well was cultured in RPMI-1640 medium containing 10% fetal bovine serum. 37°C, 5% CO 2 After 24 hours of cultivation in the environment, discard the culture medium, add the medium containing the drug, continue to cultivate for 48 hours, discard the culture medium, add pre-cooled 10% TCA, fix in the refrigerator at 4°C for 1 hour, discard the fixation solution, wash with deionized water and dry Dry, add 100 μL of 0.4% SRB dye to each well for 20 min, wash off excess SRB dye with 0.1% acetic acid solution, dry a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for resisting liver cancer by inhibiting carnitine palmityl transferase 1B (CPT1B). The drug can inhibit the growth, invasion and metastasis of liver cancer cells, and the mechanism of action is as follows: the drug inhibits the expression of the CPT1B by inhibiting a JAK / STAT3 signal path to reduce the fatty acid beta-oxidation of the liver cancer cells and reduce the production of ATP, thereby realizing the purpose of inhibiting the growth, invasion and metastasis of the liver cancer cells. The drug provides a novel therapeutic drug for the clinical treatment of the liver cancer and has a good clinical application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to an anti-liver cancer drug and its application by inhibiting the expression of carnitine acyltransferase 1B (CPT1B). Background technique [0002] Cancer is one of the most important diseases threatening human health and has become a global concern. Hepatocellular carcinoma is the fifth most common tumor in the world and the second leading cause of cancer-related death in Asia. Hepatocellular carcinoma is not easy to detect in the early stage, and it often develops to the middle and late stage when it is diagnosed clinically. The treatment is difficult and the prognosis is poor. The 5-year survival rate of patients is less than 20%. At present, there are very few anti-liver cancer drugs approved by the FDA, only sorafenib (2007) and regorafenib (2017), and the clinical efficacy is very limited. [0003] Metastasis is the main characteristic of tumor malignant behavi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/585A61P35/00A61P1/16C07J19/00
CPCA61K31/585A61P35/00A61P1/16C07J19/00
Inventor 刘云喻昌燕王梅肖毅孔庆宏孟令杰刘春娇余春波
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com